Skip to main content

Table 1 Patient demographic and baseline characteristics

From: Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

 

Comparator (N = 2288)a

BIL (N = 3584)a

Type 1 diabetes, n (%)

610 (26.7)

959 (26.8)

Age, years

54.2 ± 13.3

54.0 ± 13.3

Male,  %

58.0

54.7*

Race, n (%)

 American Indian/Alaska native

23 (1.0)

37 (1.0)

 Asian

102 (4.5)

182 (5.1)

 Black/African American

120 (5.2)

182 (5.1)

 Multiple

21 (0.9)

29 (0.8)

 Native Hawaiian/Pacific Islander

4 (0.2)

7 (0.2)

 White

2018 (88.2)

3143 (87.8)

Hispanic or Latino, n (%)

332 (14.5)

580 (16.2)

Region, n (%)

 North America

1019 (44.5)

1611 (45.0)

 European Union

834 (36.5)

1282 (35.8)

 Japan

42 (1.8)

70 (2.0)

 Other

393 (17.2)

621 (17.3)

BMI, kg/m2

30.7 ± 5.7

30.6 ± 5.7

Body weight, kg

88.6 ± 19.5

87.7 ± 19.1

Duration of diabetes, years

14.2 ± 9.4

13.8 ± 9.1

HbA1c,  %

8.2 ± 1.1

8.2 ± 1.1

Hypertension, n (%)

1588 (69.4)

2458 (68.6)

Triglycerides, mg/dL

135 ± 86

139 ± 93

Total cholesterol, mg/dL

176 ± 38

177 ± 39

LDL-C, mg/dL

97 ± 33

98 ± 33

HDL-C, mg/dL

52 ± 16

52 ± 16

History of myocardial infarction, n (%)

93 (4.2)

149 (4.4)

History of coronary revascularization, n (%)

83 (3.8)

121 (3.6)

History of coronary artery bypass graft, n (%)

56 (2.6)

92 (2.7)

Lipid lowering medication, n (%)

1274 (55.7)

1965 (54.8)

 Statin

1165 (50.9)

1787 (49.9)

 Non-statin

316 (13.8)

499 (13.9)

Smoking status, n (%)

 Never used

1279 (58.3)

2013 (59.4)

 Current used

340 (15.5)

507 (15.0)

 Ever used

575 (26.2)

867 (25.6)

  1. Mean ± SD unless otherwise specified. p value >0.05 unless specified
  2. * p = 0.031
  3. aIncludes all randomized patients